Navigation Links
Influenza Vaccine FluMist To Be Approved In Younger Children As Well

MedImmune, the company that has successfully sold flu vaccines to healthy adults in the age range of 5 to 49 is now poised on the edge of another victory . The U.S Food and Drug Administration is now about to approve the sale of FluMist targeting children younger than 5 years.

This announcement comes at a time when the company is planning to self itself to UKs AstraZeneca for 15.6 billion dollars. AstraZeneca was behind MedImmune because it did not have its own flu vaccine business. Once the deal closes, MedImmune becomes a wholly owned subsidiary of AstraZeneca.

The vaccine FluMist has had more than its share of hurdles, such as the preliminary safety concerns, being deemed unfit for young kids, and then storage problems as most pharmacies refused the drug as it needed to be stored in the freezer. This was overcome recently by a FDA-approved refrigerator safe version.

The newer version of MedImmune s FluMist appears effective for children younger than 5 years old, although safety data on the influenza vaccine is still under examination.

MedImmune sought FDA approval to market the spray for children ages 1 to 5 without a history of wheezing or asthma.

According to FDA documents, four studies conducted by MedImmune found the drug was effective against Type A and B influenza viruses, including one trial that showed the vaccine was about 90 percent effective.

Reviewers for the FDA also said one company study of the nasal spray vaccine did not signal any widespread safety problems, but results from other studies are still being reviewed. Those findings will be presented to the panel on Wednesday.

Though children who received FluMist experienced more wheezing than those who were given an inactive vaccine, "the difference between treatment groups is quite small," one reviewer said.

Other side effects included pneumonia, among other problems. Previously known side effects with FluMis t include nasal congestion, runny nose, sore throat and cough.

In a separate document, MedImmune claimed the vaccine's safety and efficacy were proven in children 24 to 59 months old and "that the risk-benefit profile for children 12 (to) 23 months of age without a history of wheeze or asthma warrants use of FluMist in this population as well."

It also said it would continue to monitor the drug in younger patients if approved.

FluMist competes with injectable flu vaccines made by GlaxoSmithKline Plc, Sanofi-Aventis' Sanofi Pasteur unit, and Chiron, which was recently acquired by Novartis AG.


'"/>




Related medicine news :

1. Influenza drug delayed
2. Chances are high for Avian Influenza virus altering its form
3. Influenza Avian Flu strain has become more contagious and dangerous.
4. A Vaccine for the impending pandemic Avian Influenza
5. Influenza Vaccination for children with neurological or neuromuscular disease
6. Avian Influenza: Government to set up expert committee
7. Resistant Influenza strains creates panic in US
8. Influenza Vaccination For The Elderly
9. Fao Declares Humans Spread Avian Influenza Virus
10. Statins Could Play Important Role In Influenza Pandemic
11. Zoo Animal Succumbs to Avian Influenza in Germany
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 ... "Better with Age: The Ultimate Guide to Brain Training" by award-winning author Phyllis ... book’s publication date is March 16, 2016. A free review copy is available ...
(Date:2/10/2016)... ... February 10, 2016 , ... IDEX Health & Science, ... stainless steel (PLS) columns combine the strength of traditional stainless steel with the ... biological samples while operating at ultra-high pressures of 20,000 psi. The higher operating ...
(Date:2/10/2016)... ... February 10, 2016 , ... The recreational use of marijuana ... the state still face a lot of restrictions as to where they can smoke ... private, personal use” and that cannabis “may not be consumed openly or publicly.” , ...
(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. Clevens, MD, ... to welcome a new addition to their growing practice. Beginning this month, Teresa ... nurse practitioner performing cosmetic procedures including injectables, fillers and laser treatments. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Steven Douglas Associates is a ... Florida Event, an upscale fundraiser held in South Florida. The Inaugural What’s Your Taste ... This year the event will be held in a new, more causal format at ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 2016  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced further details of three ... functional aspects of Lewy body dementia, a disease ... Two out of the three studies were recently ... later this quarter. In addition, the Company reported ...
(Date:2/9/2016)... Mass. , Feb. 9, 2016   AllCare ... The Joint Commission,s Gold Seal of Approval ® ... compliance with its performance standards. The Gold Seal of ... reflects an organization,s commitment to providing safe and effective ... AllCare Plus Pharmacy underwent a rigorous on-site survey ...
(Date:2/9/2016)... 9, 2016 The new report "Global Diagnostic Ultrasound Devices ... Consulting group reveals that global diagnostic ultrasound devices market was valued ... US$ 7,466.3 million by 2019 at a CAGR of 6.8% from ... ultrasound market has been analyzed for six geographies of ... Asia-Pacific , Latin America , ...
Breaking Medicine Technology: